BUSINESS CASE

Case Study: EU registration of a Biosimilar







A biopharmaceutical company located in East Asia engaged in discovering and developing biosimilar medicines, interested in entering the EU market for the first time

The project presented the following challenges:

- Setup of a multidisciplinary and integrated scientific writing team
- Definition of calendar and allocation of resources for CTD modules writing
- Bridging relevant reference medicinal product data from third-countries with EU, as well as planning and adjusting characterization studies and comparability protocols
- Reviewing biosimilarity exercise in line with EU framework
- Due to the complexity of biosimilar dossier writing, an end-to-end and fully integrated project lead was required
- Managing and planning of Centralized Procedure regulatory interactions and milestones

The CMC activities performed by Asphalion included:

- Gap analysis of existing manufacturing documentation
- Development of **CMC strategy**, including comparability and biosimilarity exercise protocols
- Pre-Submission Meeting with EMA: agreement on critical issues, such as comparability, immunogenicity data, justification of indications and extrapolation of safety/efficacy data from different indications
- Writing of all CMC DS and DP sections in a coherent and consistent manner to support central claims, such as safety, comparability and biosimilarity

Other non-CMC specific activities:

- Management of the entire MAA procedure with all administrative, operational and eCTD publishing activities until approval
- Management of translations from pre-opinion until linguistic review and opinion by agencies
- Well-planned and carefully executed project management to ensure a successful application

Successful Marketing Authorization:

- Approved indications, as desired by client
- Prescription interchangeability was granted
- Within time-to-market set goal
- Within agreed budget

